newsfilter
← Latest News
Business Wire·

Zura Bio Reports First Quarter 2026 Financial Results and Recent Corporate Updates

ZURA
  • Zura Bio Limited (NASDAQ: ZURA) reported financial results for Q1 2026, highlighting progress in two Phase 2 tibulizumab studies (TibuSHIELD for hidradenitis suppurativa & TibuSURE for systemic sclerosis) which remain on track to meet anticipated timelines.
  • The company completed an underwritten public offering in February 2026, generating approximately $144 million in gross proceeds to fund pipeline advancement.
  • As of March 31, 2026, Zura held cash and cash equivalents of $225.6 million, expected to support operations through at least the end of 2028.
  • TibuSHIELD enrollment is ongoing with approximately 225 patients, with topline data anticipated in Q4 2026.
  • TibuSURE enrollment is ongoing with approximately 80 patients, with topline data anticipated in H1 2027.
  • Zura appointed Sandeep Kulkarni, M.D. as CEO in January 2026, & added Mark Eisner, M.D., M.P.H. & Ajay Nirula, M.D., Ph.D. to its Board in February 2026.
  • Research & development expenses for Q1 2026 were $14.7 million, up from $10.5 million in Q1 2025, driven by Phase 2 tibulizumab program advancement.
  • General & administrative expenses for Q1 2026 were $10.8 million, up from $8.8 million in Q1 2025, primarily due to increased compensation & professional fees.
  • The net loss for Q1 2026 was $24.2 million ($0.22 per share), compared to $17.4 million ($0.19 per share) in the same period in 2025.
  • Additional product candidates torudokimab (ZB-880) & crebankitug (ZB-168) are being evaluated for potential development approaches across autoimmune & inflammatory conditions.